Genomic Scoring Surge Threatens Indian Labour Equity Amid Outdated Anti‑Discrimination Laws

The rapid incorporation of polygenic risk scores into corporate recruitment, insurance underwriting, and credit assessment across metropolitan centers such as Bangalore, Mumbai, and Hyderabad has catalysed a market of biometric data brokers whose valuations now rival those of traditional fintech ventures, thereby prompting economists to reassess the contribution of genomic analytics to national gross domestic product growth rates whilst simultaneously exposing a regulatory vacuum that predates the current technological surge.

Nevertheless, the extant Indian legal architecture, principally constituted by the 2005 Disability Discrimination Act and the 2015 Genetic Information Privacy Guidelines, was drafted before the advent of predictive genomics and consequently offers only a fragmented shield against employers who might wield an individual's allelic profile to justify differential treatment, a circumstance that scholars argue could erode the hard‑won gains of inclusive labour policy.

In response, several corporate watchdogs and civil‑society coalitions have petitioned the Ministry of Labour and Employment to promulgate a comprehensive Genetic Anti‑Discrimination Statute, yet bureaucratic inertia and competing priorities such as the ongoing fiscal consolidation effort have delayed substantive deliberations, leaving millions of workers and prospective applicants uncertain whether the promise of meritocratic advancement remains merely rhetorical.

If the State, whose constitutional mandate includes the protection of individual dignity and the promotion of equitable employment opportunities, continues to rely upon antiquated statutes that do not expressly forbid the utilisation of an employee’s single‑nucleotide polymorphisms in hiring algorithms, does this not betray a systemic failure that undermines public confidence in the rule of law?

Moreover, when private data‑aggregation firms, buoyed by venture capital, monetize genomic profiles without transparent consent mechanisms, can the existing consumer‑protection framework, which primarily addresses financial mis‑representation, adequately safeguard citizens against a new class of informational exploitation that may reverberate through wages, insurance premiums, and social mobility?

Consequently, should Parliament consider amending the Companies Act to impose mandatory disclosure of genetic‑risk scoring practices within corporate human‑resource policies, and would such a legislative step not simultaneously compel auditors, investors, and the broader market to evaluate the hidden costs of biologically based discrimination as part of fiduciary duty?

In light of the projected expansion of predictive‑medicine services, estimated by the Ministry of Health to generate an additional ₹12 billion in annual revenue by 2030, does the reluctance of the Securities and Exchange Board of India to require listed enterprises to report expenditures on genetic‑data procurement reflect a broader regulatory blind spot that may conceal material financial risks from shareholders?

Furthermore, if the public‑sector employers, which together account for over one‑third of urban formal employment, continue to employ automated screening tools that incorporate ancestry‑linked risk markers without a statutory audit of algorithmic fairness, can the promised efficiency gains ever be reconciled with the constitutional guarantee of equality before the law?

Thus, ought the Government of India to convene a multi‑stakeholder taskforce, comprising genomics researchers, labour economists, civil‑rights advocates, and financial regulators, to draft a cohesive policy framework that not only delineates permissible uses of genetic scores but also equips courts with the evidentiary standards necessary to adjudicate future disputes, or will the status quo persist, permitting a quiet encroachment upon personal liberty under the guise of scientific progress?

Published: May 28, 2026